HTGM - HTGM STOCK NEWS

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) will host a KOL webinar on July 27, 2022, focused on enhancing clinical development success. Dr. Robert Spitale from UC Irvine will present on RNA-based technologies in drug discovery. The webinar aims to showcase HTG's proprietary transcriptome-informed drug discovery platform, which seeks to improve the efficiency of developing small molecule drug candidates. The session will also include a live Q&A. HTG continues to advance precision medicine through its innovative profiling technology.

HTG Molecular Diagnostics (Nasdaq: HTGM) announced an amendment to its Loan and Security Agreement with Silicon Valley Bank. The amendment waives the existing minimum liquidity covenant in exchange for a partial prepayment of the outstanding principal, allowing HTG more financial flexibility through 2023. The remaining principal will amortize until the original loan maturity date. This partnership aims to enhance HTG's strategic execution in precision medicine and transcriptomic technology.

HTG Molecular Diagnostics has released a second white paper demonstrating the significance of its transcriptome-informed approach to drug design and discovery using its proprietary HTG EdgeSeq technology. The HTG Transcriptome Panel (HTP), launched in August 2021, assesses around 20,000 mRNA targets. The new white paper explores early-stage drug design, revealing indication-specific effects and potential issues related to therapeutic targets. HTG aims to use this data to refine small-molecule libraries, enhancing licensing opportunities in therapeutic areas.

HTG Molecular Diagnostics (HTGM) announced the publication of a peer-reviewed journal article in Frontiers in Medicine, showcasing the efficacy of its HTG Transcriptome Panel (HTP) in bladder cancer treatment. The research indicates that HTP's transcriptional profiling can better classify mRNA in IHC-double negative cases, offering improved treatment decisions. Given the annual incidence of ~570,000 bladder cancer cases, advancements in HTP are expected to help identify predictive biomarkers and optimize patient treatment. HTG's technology promises faster turnaround times and less sample sensitivity than RNA-Seq.

HTG Molecular Diagnostics (Nasdaq: HTGM) will sponsor a keynote presentation at the 7th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference in San Diego on June 16, 2022, at 9:05 AM PT. The presentation, titled “Implementing Biomarker Strategy in Clinical Trials,” will feature Chetan Deshpande from Pfizer, who will discuss how HTG’s EdgeSeq technology addresses clinical trial challenges. HTG focuses on advancing precision medicine through innovative transcriptome-wide profiling to enhance diagnostics and therapeutic strategies.

HTG Molecular Diagnostics (Nasdaq: HTGM) announced its HTG EdgeSeq technology was featured in several scientific abstracts at the 2022 ASCO conference in Chicago. Key presentations by biopharma customers emphasized the advantages of HTG's proprietary gene expression profiling technology, particularly the HTG Transcriptome Panel, launched in August 2021. This panel offers comprehensive human transcriptome data using minimal samples. CEO John Lubniewski reiterated the necessity of precision medicine in combating cancer. The increased visibility at ASCO reflects HTG's commitment to advancing research in this field.

HTG Molecular Diagnostics, a leader in precision medicine, is hosting a scientific webinar on June 23, 2022, at 2:00 PM ET. The webinar, titled “Integration of the HTG Transcriptome Panel into Preclinical and Clinical Programs,” will feature Dr. Pete Ansell of AbbVie, who will discuss integrating HTG's Transcriptome Panel into biomarker strategies. Marian Navratil, HTG's Senior VP of Research and Development, will present the panel's design and performance. Registration is available online.

HTG Molecular Diagnostics (HTGM) will host a scientific webinar on June 23, 2022, titled “Integration of the HTG Transcriptome Panel into Preclinical and Clinical Programs to Drive Precision Medicine Research.” The session will feature Pete Ansell, Ph.D., from AbbVie, discussing challenges faced with FFPE clinical samples and the use of HTG’s Transcriptome Panel in biomarker strategies. Marian Navratil, Ph.D., will present on the HTP design and performance based on HTG’s EdgeSeq technology. This 60-minute webinar starts at 2:00 PM ET.

HTG Molecular Diagnostics (Nasdaq: HTGM) will participate virtually in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. Management's presentation is scheduled for May 24 at 7:00 AM Eastern Time, available on demand. Attendees can also arrange one-on-one virtual meetings with management. HTG focuses on advancing precision medicine through its transcriptome-wide profiling technology, enhancing translational research and diagnostics across various diseases. For more details, visit www.htgmolecular.com.